PDF
Full
Outline
Inavolisib is a kinase inhibitor that effectively and selectively inhibits the activity of p110α and promotes the degradation of mutant p110α. In October 2024, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic breast cancer that relapses during or after completion of adjuvant endocrine therapy. Inavolisib combined with palbociclib and fulvestrant can be used to treat locally advanced or metastatic breast cancers that are phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutation, hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative, and patient population has endocrine resistance characteristics. This combination therapy shows more significant antitumor efficacy than monotherapy inavolisib. This article reviews its mechanism of action, preclinical toxicology, pharmacokinetics, clinical research, etc.
PDF
0
0
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
